Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 4.7% - What's Next?

Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) was down 4.7% on Thursday . The stock traded as low as $12.91 and last traded at $12.56. Approximately 519,153 shares were traded during trading, a decline of 63% from the average daily volume of 1,387,494 shares. The stock had previously closed at $13.18.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on CAPR shares. HC Wainwright reiterated a "buy" rating and issued a $77.00 target price on shares of Capricor Therapeutics in a report on Monday, March 17th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $30.00 price objective on shares of Capricor Therapeutics in a research note on Thursday, March 20th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $34.50.

Capricor Therapeutics Stock Performance

The company has a market cap of $431.51 million, a PE ratio of -8.95 and a beta of 4.10. The company's 50 day moving average price is $14.00 and its 200-day moving average price is $14.99.

Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its earnings results on Wednesday, March 19th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping analysts' consensus estimates of ($0.31) by $0.15. The firm had revenue of $11.13 million during the quarter, compared to analyst estimates of $9.87 million. Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. Equities research analysts expect that Capricor Therapeutics Inc will post -1.21 EPS for the current year.

Remove Ads

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Summit Investment Advisors Inc. increased its stake in shares of Capricor Therapeutics by 54.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,832 shares of the biotechnology company's stock worth $53,000 after buying an additional 1,345 shares during the period. The Manufacturers Life Insurance Company raised its stake in shares of Capricor Therapeutics by 22.4% during the fourth quarter. The Manufacturers Life Insurance Company now owns 12,919 shares of the biotechnology company's stock valued at $178,000 after acquiring an additional 2,361 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of Capricor Therapeutics by 20.5% during the fourth quarter. Invesco Ltd. now owns 14,678 shares of the biotechnology company's stock worth $203,000 after purchasing an additional 2,500 shares during the period. Russell Investments Group Ltd. grew its stake in shares of Capricor Therapeutics by 172.8% in the fourth quarter. Russell Investments Group Ltd. now owns 4,652 shares of the biotechnology company's stock worth $64,000 after purchasing an additional 2,947 shares during the last quarter. Finally, Corebridge Financial Inc. increased its holdings in Capricor Therapeutics by 32.2% during the 4th quarter. Corebridge Financial Inc. now owns 18,212 shares of the biotechnology company's stock valued at $251,000 after purchasing an additional 4,434 shares during the period. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.